Radioguided Surgery of Non-palpable Neck Lymph Node in Lymphoma Patients

Cadena-Piñeros, Enrique; Parra-Charris, Juan Sebastián

doi:10.1007/s12070-019-01591-4

Cited by 2 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Roll dissection is a secure technique for supraselective removal of recurrence in thyroid carcinoma. 11,12 Our patients presented reduction of mean levels of Tg after surgical treatment and after 6 months of second RAI treatment but did not presented statistical difference neither on the TSH or Tg levels. However, the Tg and TgAb levels showed a significant reduction independent of the TSH suppression or the values of the TgAb.…”

Section: Discussionmentioning

confidence: 54%

“…Surgery was performed by ND or radio-guided occult lesion location (ROLL) surgery. 10,11 Review of the second histopathology, included determination of the size and number of resected lymph nodes, size of the metastasis, or soft tissues and verification of extension to adjacent tissues. The second adjuvant radioiodine therapy with RAI activity, range from 100 to 200 mCi, mean of 102.7 mCi (3.7-7.4 GBq, mean of 3.8 GBq), and had postablation WBS; this dose was stablished by our tumor board according to the risk factor of each patient in relation with the 2015 ATA recommended dosage in adjuvant therapy, 3 two patients received a dose of 200 mCi dose for suspected lung metastasis that was ruled out by WBS and CT images.…”

Section: Discussionmentioning

confidence: 99%

“…Roll dissection is a secure technique for supraselective removal of recurrence in thyroid carcinoma. 11 12 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Second Adjuvant Radioiodine Therapy after Reoperation for Locoregionally Persistent or Recurrent Papillary Thyroid Carcinoma

et al. 2022

Self Cite

View full text Add to dashboard Cite

Introduction Differentiated thyroid carcinoma (DTC) has increased incidence. Intermediate- and high-risk patients have lymph node relapse rate ranging from 10 to 50%, and receive multiple reinterventions, increasing the morbidity of the disease. Currently, there are no established guidelines for the use of second radioactive iodine (RAI) therapy after the reintervention for local recurrence. Materials and Methods This is a retrospective review of the medical records of 1,299 patients treated from January 2016 to July 2019 with DTC. We included 48 patients who received total thyroidectomy, RAI remnant ablation, surgery to remove the locally recurrent/persistent papillary thyroid carcinoma (PTC), and received a second RAI therapy. Results There were no significant differences between thyroglobulin (Tg) levels before reoperation (Tg0), Tg levels postoperatively (Tg1), and Tg levels after 6 months of second adjuvant RAI therapy (Tg2). However, we evidenced a 69.79% drop in first Tg levels (Tg0: 24.7 vs. Tg1: 7.56, p=0.851) and 44.4% decrease in second Tg levels (Tg1: 7.56 vs. Tg2: 4.20, p=0.544). Also, 77.1% of the patients did not have another documented recurrence. The median relapse-free time was 10.9 months (range: 1.3–58.2 months). Conclusion The results of the study cannot assess that a second RAI treatment after reoperation for locoregionally persistent or recurrent disease have a significant impact on treatment outcomes in intermediate- or high-risk patients with PTC. However, the 77.1% of patients have not presented a second documented recurrence and the median values of Tg and TgAb levels showed a substantial decrease after surgery and second RAI treatment.

show abstract

Section: Discussionmentioning

confidence: 54%